WO1997002028A1 - Inactivation of pathogens using hydroxymethylamines - Google Patents
Inactivation of pathogens using hydroxymethylamines Download PDFInfo
- Publication number
- WO1997002028A1 WO1997002028A1 PCT/US1996/011152 US9611152W WO9702028A1 WO 1997002028 A1 WO1997002028 A1 WO 1997002028A1 US 9611152 W US9611152 W US 9611152W WO 9702028 A1 WO9702028 A1 WO 9702028A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- hydroxymethyl
- biological fluid
- blood
- hydroxymethylamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to methods for inactivation of pathogens.
- pathogens such as T-cell lymphotropic viruses (Types I and II) , cytomegalovirus, Epstein-Barr virus, the parvoviruses and P2as-nodiu- ⁇ (malaria-causing) protozoa
- T-cell lymphotropic viruses Types I and II
- cytomegalovirus Epstein-Barr virus
- P2as-nodiu- ⁇ malaria-causing protozoa
- the HIV virus is illustrative of a pathogen that, until recently, was not even recognized.
- pasteurization One such technique which has been used to inactivate viruses in blood and/or blood products is pasteurization.
- the pasteurization of blood and/or blood products is most often effected by heating them in the liquid state for 10 hours at 60°C.
- a small amount of protein stabilizer, such as caprylate or tryptophanate, is often added to the preparation. After pasteurization has been completed, the stabilizer typically must be removed from the preparation prior to its clinical use.
- pasteurization is more effective in inactivating enveloped viruses (i.e., viruses having a lipid envelope surrounding the viral capsid) than in inactivating non-enveloped viruses (i.e., viruses which lack a lipid envelope surrounding the viral capsid) .
- Another technique which has been used to inactivate viruses in blood and/or blo ⁇ d products is the solvent/detergent (S/D) method.
- S/D solvent/detergent
- the S/D method which is limited to use in inactivating enveloped viruses, Involves treating a blood preparation with an organic mixture which disrupts the lipid envelope of enveloped viruses .
- the disruption of the lipid envelope leads either to complete structural disruption of the virus or to destruction of the cell receptor recognition site on the virus. In either case, the virus is rendered noninfectious.
- the solvent used in the S/D method is most often tri- (n-butyl)phosphate (TNBP) , and the detergent is either Tween 80°, Triton X-100 C or sodium deoxycholate.
- TNBP tri- (n-butyl)phosphate
- the detergent is either Tween 80°, Triton X-100 C or sodium deoxycholate.
- Temperature and time influence the efficacy of the S/D method, typical temperatures being in the range of 24° C to 37°C, and the typical duration of treatment being at least 6 hours.
- Still another technique which has been used to inactivate viruses in blood and/or blood products is photochemical inactivation.
- Virus Inactivated Single-Donor Fresh Plasma Preparations " Infusiontherapie, 19:79-83 (1993) ;
- Wagner et al. "Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization, " Transfusion, 34 (6) :521-526 (1994);
- Wagner et al. "Red cell alterations associated with virucidal methylene blue phototreatment, " Transfusion, 33:3 * 0-36 (1993); Mohr et al.
- the photochemical inactivation of a blood preparation typically involves treating the blood preparation with a photoactivatable chemical and then irradiating the preparation with light of a sufficient wavelength to activate the photoactivatable chemical.
- photoactivatable chemicals used in the photochemical inactivation of viruses present in blood preparations include psoralens, hypericin, methylene blue and toluidine blue.
- psoralens which have an affinity for nucleic acids, inactivate viruses by intercalating between viral nucleic acid base pairs and, in the presence of UVA light, forming a covalent bond with the viral nucleic acid, thereby preventing its transcription and/or replication.
- the manner in which hypericin, methylene blue and toluidine blue inactivate viruses is not as well- defined as that for psoralens.
- these chemicals when photoactivated, generate the highly reactive entity, singlet oxygen, which then attacks the cellular structure (e.g. viral envelope) of the virus.
- Viral inactivation agents are substances that render viruses incapable of replication and proliferation. From the literature discussed above, one may conclude that viral inactivating compounds have been identified which are specifically toxic to blood borne viruses such that cells and proteins are not adversely affected. Still it is important to limit exposure of biological samples to viral inactivation agents, such as, for example, psoralens, hypericin, methylene blue, toluidine blue or a combination of tri- (n-butyl) phosphate and a detergent such as Tween 80, Triton X-100 or sodium deoxycholate to the minimum extent necessary to reduce potentially signification interactions that could lead to undesirable side effects .
- U.S. Patent 4,337,269 (Berke et al.
- hydroxymethylaminoacetate also referred to herein as hydroxymethylglycinate
- hydroxymethylglycinate is said to be effective at inhibiting the growth of bacteria, yeasts and molds in a variety of substances susceptible to microbial contamination, such as cosmetics, foodstuffs, pharmaceuticals, paints, cutting oils or fluids, agricultural products, oil .drilling fluids, paper industry, embalming solutions, cold sterilization medical and dental equipment, cooling towers, fabric impregnation, latexes, swimming pools, inks, household disinfectants, waxes and polishes, toilet bowl cleaners, bathroom cleaners, laundry detergents, soaps, wood preservatives, hospital and medical antiseptics and adhesives.
- substances susceptible to microbial contamination such as cosmetics, foodstuffs, pharmaceuticals, paints, cutting oils or fluids, agricultural products, oil .drilling fluids, paper industry, embalming solutions, cold sterilization medical and dental equipment, cooling towers, fabric impregnation, latexes, swimming pools, inks, household disinfectants, waxes and polishes,
- Sodium hydroxymethylglycinate is the active ingredient in the preservative SUTTOCIDETMA, which is commercially available from Sutton Laboratories, Chatham, New Jersey. In certain promotional literature published by Sutton Laboratories, SUTTOCIDETMA is said to be active against Gram- negative and Gram-positive bacteria, yeast and mold and is suggested for use as a preservative in shampoos, hair conditioners and facial treatments.
- U.S. Patent 4,980,176 (Berke et al . ) disclosed a composition containing one or more 3-isothiazolones and a compound which is a member selected from the group consisting of hydroxymethyl-aminoacetic acid, its salts and lower alkyl esters.
- the aforementioned composition is described in the patent as being effective against bacteria, yeasts and molds.
- Suggested applications in the patent for the above- described composition include use as a preservative in cosmetics, toiletries and household cleaning products, use as a biocide for synthetic latexes, emulsion paints and other coatings, adhesives, polishes, carpet backing compositions, surfactants, metalworking fluids, industrial and domestic water treatment including cooling tower systems and swimming pools, adhesive mats, drilling mud formulations, painting pastes, spin finish emulsions, polymer dispersions and fuels and as a slimicide for slime control in the manufacture of paper from wood pulp.
- the present invention is a method of inactivating a virus in a biological fluid, such as blood.
- the biological fluid is contacted with a hydroxymethylamine (HMA) in sufficient quantity to inactivate the virus (i.e.-, an effective amount) .
- HMA hydroxymethylamine
- the biological fluid can be of any type including, but not- / limited to, whole blood and a wide variety of blood components, including, but not limited to, red blood cells, red blood cell concentrate, platelets, platelet concentrate, platelet rich plasma, platelet poor plasma, source plasma (plasmaphoresis plasma) , fresh frozen plasma, plasma proteins (e.g., clotting factors VIII, X, etc.) , and other body fluids, such as lymph, cerebrospinal fluid, semen, saliva, etc. While targeted at the inactivation of viruses, the method is effective against other microorganisms as well. These microorganisms can be pathogenic or nonpathogenic and include bacteria, yeasts, molds and protozoa.
- this invention provides a method for inactivating a microorganism contained in a biological fluid.
- the method comprises the step of contacting the microorganism with an effective amount of a hydroxymethylamine (HMA) .
- HMA hydroxymethylamine
- Suitable hydroxy- methylamines include compounds of Formula (I) R ⁇
- the invention in another aspect, relates to a method of processing a biological fluid intended for administration to an individual in need thereof.
- the method comprises the steps of: (a) treating the biological fluid with an effective amount of a pathogen-inactivating hydroxymethylamine, thereby producing a treated biological fluid; and (b) then removing free hydroxymethylamine from the treated biological fluid.
- the invention relates to a method of treating an individual in need of a biological fluid. The method comprises the steps" of: (a) treating the biological fluid with an effective amount of a pathogen-inactivating hydroxymethylamine, thereby producing a treated biological fluid; and (b) administering the treated biological fluid to the individual in need thereof.
- the present invention relates to the method of use of HMA' s as pathogen-inactivating agents, particularly viral-inactivating agents, in biological samples, such as blood or blood products.
- T4 stock Two hundred twenty-five microliters of T4 stock were added to each of twelve tubes. 4.75 ⁇ L of whole blood were added to three of the tubes, 4.75 ⁇ L of plasma were added to another " three of the tubes and 4.75 ⁇ L of PBS were added to still another three of the tubes, the remaining three tubes serving as controls. 25 ⁇ L of a 50% solution of hydroxymethylglycinate were added to each of the tubes, except for the controls. The various mixtures were incubated at room temperature, and at the times indicated below samples were taken, diluted, mixed with h ⁇ st cells and overlaid onto solid medium. After overnight incubation at 37"C, plaques were counted. The results are summarized below in TABLE III.
- EXAMPLE 10 10 ⁇ L of T4 virus stock and 89 ⁇ L of blood plasma were added to each of seven tubes. 1 ⁇ L of an appropriate hydroxymethylvaline stock solution was added to each of three of the plasma-containing tubes and 1 ⁇ L of an appropriate hydroxymethylaspartate stock solution was added to each of another three of the plasma-containing tubes to give the below-listed concentrations. 1 ⁇ L of a buffer solution was added to the remaining tube as a control . After incubation at 30 * C for 1 hour, samples from each tube were taken, diluted, mixed with host cells, and overlaid onto solid medium. After overnight incubation at 37°C, plaques were counted. The results are summarized below in TABLE X.
- T4 virus stock and blood plasma were added to each of six tubes in the manner described above. Hydroxymethyl-o-phosphorylethanolamine was added to each of two tubes, hydroxymethyl-trp-gly-gly was added to each of another two tubes, and a buffer containing no inhibitor was added to each of the remaining two tubes. The mixtures were incubated at 30 * C. At the times indicated below, samples were taken from each tube, diluted, and plated. After overnight incubation at 37 * C, plaques were counted. The results are summarized below in TABLE XI. TABLE XI
- EXAMPLE 13 465 ⁇ L of blood plasma, 30 ⁇ L of T4 stock solution were added to each of eight tubes. 5 ⁇ L of a 50% solution of hydroxymethylcysteine were added to each of two tubes. 5 ⁇ L of a 50% solution of hydro ⁇ xymethyl-aminophenyl acetic acid were added to each of another two tubes. 5 ⁇ L of a 50% solution of hydroxymethylaminoethanol were added to each of another two tubes. 5 ⁇ L of a buffer solution serving as a control were added to each of the two remaining tubes. The mixtures were incubated at 30 * C. At the times indicated below, samples were taken, diluted, mixed with host cells and overlaid onto solid medium. After overnight incubation at 37'C, plaques were counted. The results are summarized below in TABLE XIII.
- EXAMPLE 17 465 ⁇ L of blood plasma and 30 ⁇ L of T4 were added to each of six tubes. 5 ⁇ L of hydroxymethyl- phosphonomethylglycine were added to each of two tubes, and 5 ⁇ L of hydroxymethylmethylhydantion were added to each of another two tubes. 5 ⁇ L of buffer were added to each of the remaining two tubes. The mixtures were incubated at 30 * C. At the times indicated below, samples were taken, diluted, mixed with host cells and overlaid onto solid medium. After overnight incubation at 37 * C, plaques were counted. The results are summarized below in TABLE XVII.
- EXAMPLE 20 The virucidal activities of hydroxymethylphospho- nomethylglycinate and hydroxymethylglycinamide, respectively, were tested in the manner described above at the concentrations indicated below. The results are summarized below in TABLE XX. TABLE XX
- V is a virus.
- a large excess of HMG was present in the reaction conditions and therefore a pseudo first order equation could be used. Furthermore, it was assumed that in a blood bag, no mass transfer effects exist which would affect the reaction kinetics.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9505265A JPH10506927A (en) | 1995-06-29 | 1996-07-01 | Pathogen inactivation using oxymethylamine |
EP96940235A EP0792146A1 (en) | 1995-06-29 | 1996-07-01 | Inactivation of pathogens using hydroxymethylamines |
BR9606454A BR9606454A (en) | 1995-06-29 | 1996-07-01 | Method of inactivating a microorganism in a biological fluid method of processing a biological fluid intended for administration to an individual in need of it method of treating an individual in need of a biological fluid and method of treating a biological fluid |
AU77173/96A AU7717396A (en) | 1995-06-29 | 1996-07-01 | Inactivation of pathogens using hydroxymethylamines |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49647895A | 1995-06-29 | 1995-06-29 | |
US08/496,478 | 1995-06-29 | ||
US52665895A | 1995-09-11 | 1995-09-11 | |
US08/526,658 | 1995-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997002028A1 true WO1997002028A1 (en) | 1997-01-23 |
Family
ID=27052134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/011152 WO1997002028A1 (en) | 1995-06-29 | 1996-07-01 | Inactivation of pathogens using hydroxymethylamines |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0792146A1 (en) |
JP (1) | JPH10506927A (en) |
AU (1) | AU7717396A (en) |
BR (1) | BR9606454A (en) |
CA (1) | CA2198085A1 (en) |
WO (1) | WO1997002028A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093725A (en) * | 1997-01-06 | 2000-07-25 | Cerus Corporation | Frangible compounds for pathogen inactivation |
US6270952B1 (en) | 1998-01-06 | 2001-08-07 | Cerus Corporation | Methods for quenching pathogen inactivators in biological materials |
WO2001058496A1 (en) * | 2000-02-11 | 2001-08-16 | Allied Therapeutics Limited | System for the extracorporeal treatment of blood |
US6410219B1 (en) | 1994-11-14 | 2002-06-25 | Cerus Corporation | Treating blood or blood products with compounds which have a mustard, azirdinium or aziridine group and a nucleic acid binding group |
WO2002092139A1 (en) * | 2001-05-14 | 2002-11-21 | Akzo Nobel N.V. | Methods for inactivating viruses |
US6514987B1 (en) | 1997-01-06 | 2003-02-04 | Cerus Corporation | Frangible compounds for pathogen inactivation |
WO2003059062A1 (en) * | 2002-01-18 | 2003-07-24 | Lonza Ag | Virucidal disinfectant |
US7655392B2 (en) | 2004-10-29 | 2010-02-02 | Cerus Corporation | Quenching methods for red blood cell inactivation process |
CN101885740A (en) * | 2009-05-11 | 2010-11-17 | 李坚 | New preparation method of herbicide glyphosate |
US8900805B2 (en) | 2008-04-09 | 2014-12-02 | Cerus Corporation | Quenching methods for red blood cell pathogen inactivation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110317230B (en) * | 2018-03-30 | 2023-11-07 | 上海昇悦医药科技有限公司 | Phosphate derivatives and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3239415A (en) * | 1963-01-14 | 1966-03-08 | Upjohn Co | Methods of reducing virus titers in animals with adenine derivatives |
DE2135542A1 (en) * | 1971-07-16 | 1973-01-25 | Boehringer Mannheim Gmbh | Virustatic benzthiazole-2-thione derivs - active against both dna and rna viruses |
US3981772A (en) * | 1974-08-27 | 1976-09-21 | Poverenny Alexandr Mikhailovic | Method of attenuating viruses with simultaneous stabilization of their antigens using selected aminomethylol compounds |
WO1981000188A1 (en) * | 1979-07-23 | 1981-02-05 | Sutton Lab Inc | Preservative compositions |
JPS62195304A (en) * | 1986-02-24 | 1987-08-28 | Dainippon Ink & Chem Inc | Industrial antiseptic |
US4833165A (en) * | 1987-10-07 | 1989-05-23 | Louderback Allan Lee | Method of inactivating HTLV-III virus in blood |
-
1996
- 1996-07-01 JP JP9505265A patent/JPH10506927A/en active Pending
- 1996-07-01 BR BR9606454A patent/BR9606454A/en not_active Application Discontinuation
- 1996-07-01 EP EP96940235A patent/EP0792146A1/en not_active Withdrawn
- 1996-07-01 AU AU77173/96A patent/AU7717396A/en not_active Abandoned
- 1996-07-01 CA CA002198085A patent/CA2198085A1/en not_active Abandoned
- 1996-07-01 WO PCT/US1996/011152 patent/WO1997002028A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3239415A (en) * | 1963-01-14 | 1966-03-08 | Upjohn Co | Methods of reducing virus titers in animals with adenine derivatives |
DE2135542A1 (en) * | 1971-07-16 | 1973-01-25 | Boehringer Mannheim Gmbh | Virustatic benzthiazole-2-thione derivs - active against both dna and rna viruses |
US3981772A (en) * | 1974-08-27 | 1976-09-21 | Poverenny Alexandr Mikhailovic | Method of attenuating viruses with simultaneous stabilization of their antigens using selected aminomethylol compounds |
WO1981000188A1 (en) * | 1979-07-23 | 1981-02-05 | Sutton Lab Inc | Preservative compositions |
JPS62195304A (en) * | 1986-02-24 | 1987-08-28 | Dainippon Ink & Chem Inc | Industrial antiseptic |
US4833165A (en) * | 1987-10-07 | 1989-05-23 | Louderback Allan Lee | Method of inactivating HTLV-III virus in blood |
Non-Patent Citations (6)
Title |
---|
A.C. BUCK: "THE USE OF NOXYTHIOLIN AS AN ANTISEPTIC IRRIGANT IN UPPER URINARY TRACT DRAINAGE FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY", BRITISH JOURNAL OF UROLOGY, vol. 62, no. 4, 1988, pages 306 - 310, XP002017825 * |
DATABASE WPI Section Ch Week 8740, Derwent World Patents Index; Class A60, AN 87-280956, XP002017826 * |
E.V. MITSEVICH ET AL.: "EFFECT OF FORMALDEHYDE AND ITS AMINOMETHYLOL DERIVATIVES ON STRAINS OF ESCHERICHIA COLI WITH VARIOUS DEFECTS OF DNA REPAIR SYSTEMS", BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 87, no. 5, 1979, pages 489 - 491, XP002017822 * |
G. GARRIGUE ET AL.: "STUDY OF THE IN VITRO VIRUCIDAL ACTIVITY OF NOXYTIOLIN", REVUE DE L'INSTITUT PASTEUR DE LYON, vol. 13, no. 2, 1980, pages 209 - 215, XP002017824 * |
J.I. BLENKARHN ET AL.: "IN-VITRO ANTIBACTERIAL ACTIVITY OF NOXYTHIOLIN AND TAUROLIDINE", JOURNAL OF PHARMACY & PHARMACOLOGY, vol. 42, no. 8, 1990, pages 589 - 590, XP002017823 * |
M.J. GIDLEY ET AL.: "MECHANISMS OF ANTIBACTERIAL FORMALDEHYDE DELIVERY FROM NOXYTHIOLIN AND OTHER "MASKED-FORMALDEHYDE" COMPOUNDS", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 35, no. 11, 1983, pages 712 - 717, XP002017821 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410219B1 (en) | 1994-11-14 | 2002-06-25 | Cerus Corporation | Treating blood or blood products with compounds which have a mustard, azirdinium or aziridine group and a nucleic acid binding group |
US6093725A (en) * | 1997-01-06 | 2000-07-25 | Cerus Corporation | Frangible compounds for pathogen inactivation |
US6514987B1 (en) | 1997-01-06 | 2003-02-04 | Cerus Corporation | Frangible compounds for pathogen inactivation |
US6709810B2 (en) | 1998-01-06 | 2004-03-23 | Cerus Corporation | Methods for quenching pathogen inactivators in biological materials |
US6270952B1 (en) | 1998-01-06 | 2001-08-07 | Cerus Corporation | Methods for quenching pathogen inactivators in biological materials |
US7293985B2 (en) | 1998-01-06 | 2007-11-13 | Cerus Corporation | Methods for quenching pathogen inactivators in biological materials |
WO2001058496A1 (en) * | 2000-02-11 | 2001-08-16 | Allied Therapeutics Limited | System for the extracorporeal treatment of blood |
WO2002092139A1 (en) * | 2001-05-14 | 2002-11-21 | Akzo Nobel N.V. | Methods for inactivating viruses |
US6635679B2 (en) | 2001-05-14 | 2003-10-21 | Akzo Nobel N.V. | Methods and compositions for inactivating viruses |
WO2003059062A1 (en) * | 2002-01-18 | 2003-07-24 | Lonza Ag | Virucidal disinfectant |
US8221733B2 (en) | 2002-01-18 | 2012-07-17 | Lonza Ag | Virucidal disinfectant |
US7655392B2 (en) | 2004-10-29 | 2010-02-02 | Cerus Corporation | Quenching methods for red blood cell inactivation process |
US8900805B2 (en) | 2008-04-09 | 2014-12-02 | Cerus Corporation | Quenching methods for red blood cell pathogen inactivation |
US9713627B2 (en) | 2008-04-09 | 2017-07-25 | Cerus Corporation | Pathogen-inactivated red blood cell compositions |
US10357516B2 (en) | 2008-04-09 | 2019-07-23 | Cerus Corporation | Pathogen-inactivated red blood cell compositions |
CN101885740A (en) * | 2009-05-11 | 2010-11-17 | 李坚 | New preparation method of herbicide glyphosate |
CN101885740B (en) * | 2009-05-11 | 2015-07-01 | 李坚 | New preparation method of herbicide glyphosate |
Also Published As
Publication number | Publication date |
---|---|
JPH10506927A (en) | 1998-07-07 |
EP0792146A1 (en) | 1997-09-03 |
AU7717396A (en) | 1997-02-05 |
CA2198085A1 (en) | 1997-01-23 |
BR9606454A (en) | 1997-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5244083B2 (en) | Brittle compounds for pathogen inactivation | |
US11426479B2 (en) | Device and method for sterilization of instruments and surfaces | |
Wainwright | The emerging chemistry of blood product disinfection | |
Wainwright | Pathogen inactivation in blood products | |
Pelletier et al. | Pathogen inactivation techniques | |
US6093725A (en) | Frangible compounds for pathogen inactivation | |
US6270952B1 (en) | Methods for quenching pathogen inactivators in biological materials | |
CA2397862C (en) | Storage solution containing photosensitizer for inactivation of biological contaminants | |
Casteel et al. | Photoinactivation of Hepatitis A Virus by Synthetic Porphyrins¶ | |
US20040029897A1 (en) | Frangible compounds for pathogen inactivation | |
WO1997002028A1 (en) | Inactivation of pathogens using hydroxymethylamines | |
KR102419286B1 (en) | Modification of extracorporeal photopheresis technology with porphyrin precursors | |
OA11633A (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers. | |
US20030113704A1 (en) | Methods for inactivation of pathogens in biological materials | |
US20020042043A1 (en) | Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity | |
JP2004520448A (en) | Virus inactivation method using antioxidants | |
US6090599A (en) | Viral inactivation treatment of red blood cells using phthalocyanines and red light | |
US20020022215A1 (en) | Inactivation of small non-enveloped viruses and other microbial pathogens by porphyrins | |
GB2373787A (en) | Phenothiazinium derivatives and their use to reduce pathogenic contaminants | |
Ben-Hur et al. | Pathogen reduction in blood for transfusion using photodynamic treatments | |
JPH11506029A (en) | Methods for inactivating viral and bacterial blood contaminants | |
US20040014738A1 (en) | Method of inactivating micro-organisms | |
US20060269907A1 (en) | Decontamination of biological fluids using diphenylpyrilium compounds | |
WO2002030190A1 (en) | Method of inactivating viral particles in a blood product | |
WO1996028025A1 (en) | Inactivation of pathogens in blood and/or blood products using formaldehyde |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2198085 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996940235 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996940235 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996940235 Country of ref document: EP |